Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression

Journal of General Virology

Volumn 77, Issue 10, 1996, Pages 2403-2414

  Schreiber, Michael ^a   Wachsmuth, Christoph ^a   Müller, Harm ^a   Hagen, Christiane ^a   Schmitz, Herbert ^a   Van Lunzen, Jan ^a,b  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN GP 120; VIRUS GLYCOPROTEIN; VIRUS RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; T LYMPHOCYTE; VARIANCE; VIRION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029956382     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-77-10-2403     Document Type: Article

References (47)

1. Albert, J., Abrahamsson, B., Nagy, K., Aurelius, E., Gaines, H., Nystrom, G. & Fenyo, E. M. (1990). Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4, 107-112.
2. Allain, J. P., Laurian, Y. & Paul, D. A. (1987). Long-term evaluation of HIV antigen and antibody to p24 and gp41 in patients with haemophilia. New England Journal of Medicine 317, 1114-1121.
3. Anders, R. F. (1986). Multiple cross-reactivities amongst antigens of Plasmodium falciparum impair the development of protective immunity against malaria. Parasite Immunology 8, 529-539.
4. Berman, P. W., Groopman, J. E., Gregory, T., Clapham, P., Weiss, R. A., Ferriani, R., Riddle, L., Shimasaki, S., Lucas, C., Lasky, L. A. & Eichberg, J.W. (1988). HIV-1 challenge of chimpanzees immunized with recombinant gp120. Proceedings of the National Academy of Sciences, USA 85, 5200-5204.
5. Carrow, E. W., Vujcic, L. K., Glass, W. L., Seamon, K. B., Rastogi, S. C., Hendry, R. M., Boulos, R., Nzila, N. & Quinnan, G. V., Jr (1991). High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1 MN in sera from Africa and the Americas. AIDS Research and Human Retroviruses 7, 831-838.
6. Cavacini, L. A., Emes, C. L., Power, J., Underdahl, J., Goldstein, R., Mayer, K. & Posner, M. R. (1993). Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression. Journal of Acquired Immune Deficiency Syndromes 6, 1093-1102.
7. Coombs, R. W., Collier, A. C., Allain, J. P., Nikora, B., Leuther, M., Gjerset, G. F. & Corey, L. (1989). Plasma viremia in human immunodeficiency virus infection. New England Journal of Medicine 321, 1626-1631.
8. Fenouillet, E., Blanes, N., Coutellier, A. & Glückmann, J. C. (1993). Relationship between anti-p24 antibody levels and p24 antigenaemia in HIV-infected patients. AIDS Research and Human Retroviruses 9, 1251-1255.
9. Fenouillet, E., Blanes, N., Benjouad, A. & Glückman, J. C. (1995). Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity. Clinical and Experimental Immunology 99, 419-424.
10. Girard, M., Kieny, M. P., Pinter, A., Barre-Sinoussi, F., Nara, P., Kobe, H., Kusumi, K., Chaput, A., Reinhart, T., Muchmore, E., Ronco, J., Kaczonek, M., Garrard, E., Gluckman, J. C. & Fultz, P. N. (1991). Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 88, 542-546.
11. Goudsmit, J., Debouck, C., Meloen, R. H., Smit, L., Bakker, M., Asher, D. M., Wolff, A. V., Gibbs, C. J., Jr & Gajdusek, D. C. (1988). Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicts early type-specific antibodies in experimentally infected chimpanzees. Proceedings of the National Academy of Sciences, USA 85, 4478-4482.
12. Goudsmit, J., Kuiken, C. L. & Nara, P. L. (1989). Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection. AIDS 3, S119-S123.
13. Gradoni, L., Scalone, A. & Gramiccia, M. (1993). HIV-Leishmania coinfections in Italy: serological data as an indication of the sequence of acquisation of the two infections. Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 94-96.
14. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M. & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
15. Hogervorst, E., Jurriaans, S., De Wolf, F., Van Wijk, A., Wiersma, A., Valk, M., Roos, M., Van Gemen, B., Coutinho, R., Miedema, F. & Goudsmit, J. (1995). Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24- specific but not V3-specific antibody levels. Journal of Infectious Diseases 171, 811-821.
16. Homsy, J., Meyer, M. & Levy, J. A. (1990). Serum enhancement of human immunodeficiency virus (HIV) correlates with disease in HIV-infected individuals. Journal of Virology 64, 1437-1440.
17. Jiang, S. B., Lin, K. & Neurath, A. R. (1991). Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41 [Erratum appears in vol. 175, p. 621]. Journal of Experimental Medicine 174, 1557-1563.
18. Kliks, S. C., Shioda, T., Haigwood, N. L. & Levy, J.A. (1993). V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences, USA 90, 11518-11522.
19. Kostrikis, L. G., Cao, Y., Ngai, H., Moore, J. P. & Ho, D. D. (1996). Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. Journal of Virology 70, 445-458.
20. Lange, J. M. A., Paul, D. A., Huisman, H. G., De Wolf, F., Van Den Berg, H., Coutinho, R. A., Danner, S. A., Van Der Noordaa, J. & Goudsmit, J. (1986). Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. British Medical Journal 293, 1459-1462.
21. LaRosa, G. J., Davide, J. P., Weinhold, K., Waterbury, J. A., Profy, A. T., Lewis, J. A., Langlois, A. J., Dreesman, G. R., Boswell, R. N., Shadduck, P., Holley, L. H., Karplus, M., Bolognesi, D. P., Matthews, T. J., Emini, E. A. & Putney, S. D. (1990). Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249, 932-935.
22. Layne, S. P., Merges, M. J., Dembo, M., Spouge, J. L., Conley, S. R., Moore, J. P., Raina, J. L., Renz, H., Gelderblom, H. R. & Nara, P. L. (1992). Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 189, 695-714.
23. Lu, W., Shin, W. K., Tourani, J.-M., Eme, D., Alter, H. J. & Andrieu, J.-M. (1993). Lack of isolate-specific neutralizing activity is correlated with an increased viral burden in rapidly progressing HIV-1- infected patients. AIDS 7, S91-S99.
24. Macatonia, S. E., Lau, R., Patterson, S., Pinching, A. J. & Knight, S. C. (1990). Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology 71, 38-45.
25. McKeating, J. A., Gow, J., Goudsmit, J., Pearl, L. H., Mulder, C. & Weiss, R. A. (1989). Characterization of HIV-1 neutralization escape mutants. AIDS 3, 777-784.
26. Maggi, E., Mazzetti, M., Ravina, A., Annunziato, F., De Carli, M., Piccini, M. P., Manetti, R., Carbonari, M., Pesce, A. M., Del Prete, G. & Romagnani, S. (1994). Ability of HIV to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells. Science 265, 244-248.
27. Montefiori, D. C., Graham, B. S., Kliks, S. & Wright, P. F. (1992). Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. Journal of Clinical Immunology 12, 429-439.
28. Moore, J. P., Cao, Y., Ho, D. D. & Koup, R. A. (1994). Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. Journal of Virology 68, 5142-5155.
29. Moore, J. P., Cao, Y., Leu, J., Qin, L., Korber, B. & Ho, D. D. (1996). Inter- and intraclade neutralization of human immunodeficiency virus type 1 : genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. Journal of Virology 70, 427-444.
30. Najera, I., Holguin, A., Quinones Mateu, M. E., Munoz Fernandez, M. A., Najera, R., Lopez Galindez, C. & Domingo, E. (1995). Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. Journal of Virology 69, 23-31.
31. Nara, P. L., Smit, L., Dunlop, N., Hatch, W., Merges, M., Waters, D., Kelliher, J., Gallo, R. C., Fischinger, P. J. & Goudsmit, J. (1990). Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. Journal of Virology 64, 3779-3791.
32. Page, M., Vella, C., Corcoran, T., Dilger, P., Ling, C., Heath, A. & Thorpe, R. (1992). Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS. AIDS 6, 441-446.
33. Piatak, M., Saag, M. S., Jr, Yang, L. C., Kappes, J. C., Luk, K. C., Hahn, B. H., Shaw, G. M. & Lifson, J. D. (1993). High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259, 1749-1754.
34. Pincus, S. H., Messer, K. G., Nara, P. L., Blattner, W. A., Colclough, G. & Reitz, M. (1994). Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. Journal of Clinical Investigation 93, 2505-2513.
35. Pircher, H., Moskophidis, D., Rohrer, U., Burki, K., Hengartner, H. & Zinkernagel, R. M. (1990). Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 346, 629-633.
36. Pulendran, B., Smith, K. G. C. & Nossal, G. J. V. (1995). Soluble antigen can impede affinity maturation and the germinal center reaction but enhance extrafollicular immunoglobulin production. Journal of Immunology 155, 1141-1150.
37. Rinaldo, C., Huang, X. L., Fan, Z., Ding, M., Beltz, L., Logar, A., Panicali, D., Mazzara, G., Liebmann, J., Cottrill, M. & Gupta, P. (1995). High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term non-progressors. Journal of Virology 69, 5838-5842.
38. Rosenberg, Z. F. & Fauci, A. S. (1988). Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infections. Annals of the New York Academy of Sciences 546, 164-174.
39. + memory cells by human immunodeficiency virus type 1 : evidence for a role in the selective T-cell functional defects observed in infected individuals. Proceedings of the National Academy of Sciences, USA 87, 6058-6062.
40. Schreiber, M., Petersen, H., Wachsmuth, C., Müller, H., Hufert, F. T. & Schmitz, H. (1994). Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum, Journal of Virology 68, 3908-3916.
41. Spear, G. T., Takefman, D. M., Sharpe, S., Ghassemi, M. & Zolla Pazner, S. (1994). Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 204, 609-615.
42. Strunnikova, N., Ray, S. C., Livingston, R. A., Rubalcaba, E. & Viscidi, R. P. (1995). Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression. Journal of Virology 69, 7548-7558.
43. von Gegerfelt, A., Albert, J., Morfeldt-Manson, L., Broliden, K. & Fenyo, E. M. (1991). Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology 185, 162-168.
44. Wabwire Mangen, F., Shiff, C. L., Valhov, D., Kline, R., Serwadda, D., Sewankambo, N. K., Mugerwa, R. D. & Quinn, T. C. (1989). Immunological effects of HIV-1 infection on the humoral response to malaria in an Africa population. American Journal of Tropical Medicine and Hygiene 41, 5504-5511.
45. Wain Hobson, S. (1995). Virological mayhem. Nature 373, 102.
46. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S. & Shaw, G. M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
47. Zwart, G., Langedijk, H., Van Der Hoek, L., De Jong, J. J., Wolfe, T. F. W., Ramautarsing, C., Bakker, M., De Ronde, A. & Goudsmit, J. (1991). Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 181, 481-489.